Merdad Parsey Sells 2,000 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) Stock

Gilead Sciences, Inc. (NASDAQ:GILDGet Free Report) insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $72.96, for a total value of $145,920.00. Following the transaction, the insider now owns 96,304 shares in the company, valued at approximately $7,026,339.84. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Merdad Parsey also recently made the following trade(s):

  • On Wednesday, February 28th, Merdad Parsey sold 2,000 shares of Gilead Sciences stock. The stock was sold at an average price of $73.18, for a total value of $146,360.00.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $70.89 on Thursday. The stock has a fifty day moving average price of $74.31 and a 200 day moving average price of $77.18. The stock has a market cap of $88.26 billion, a PE ratio of 15.75, a P/E/G ratio of 0.92 and a beta of 0.19. Gilead Sciences, Inc. has a 1 year low of $70.70 and a 1 year high of $87.86. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.27 and a current ratio of 1.43.

Gilead Sciences (NASDAQ:GILDGet Free Report) last issued its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.76 by ($0.04). The firm had revenue of $7.12 billion for the quarter, compared to analyst estimates of $7.10 billion. Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The business’s revenue for the quarter was down 3.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.67 earnings per share. Sell-side analysts forecast that Gilead Sciences, Inc. will post 7.07 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 28th. Investors of record on Friday, March 15th were issued a dividend of $0.77 per share. The ex-dividend date of this dividend was Thursday, March 14th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.75. This represents a $3.08 annualized dividend and a yield of 4.34%. Gilead Sciences’s payout ratio is currently 68.44%.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Royal Bank of Canada dropped their price target on Gilead Sciences from $76.00 to $75.00 and set a “sector perform” rating on the stock in a research note on Wednesday, February 14th. Wells Fargo & Company lowered their target price on Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating on the stock in a research note on Monday, March 4th. StockNews.com upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, March 26th. Cantor Fitzgerald lowered their target price on Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 7th. Finally, Truist Financial downgraded Gilead Sciences from a “buy” rating to a “hold” rating and lowered their target price for the company from $91.00 to $82.00 in a research note on Thursday, February 22nd. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $85.36.

Check Out Our Latest Research Report on Gilead Sciences

Institutional Trading of Gilead Sciences

Several institutional investors and hedge funds have recently made changes to their positions in GILD. Cetera Investment Advisers lifted its position in shares of Gilead Sciences by 9.2% in the first quarter. Cetera Investment Advisers now owns 57,967 shares of the biopharmaceutical company’s stock valued at $3,446,000 after acquiring an additional 4,877 shares in the last quarter. Baird Financial Group Inc. lifted its position in shares of Gilead Sciences by 3.9% in the first quarter. Baird Financial Group Inc. now owns 448,409 shares of the biopharmaceutical company’s stock valued at $26,660,000 after acquiring an additional 16,643 shares in the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its position in shares of Gilead Sciences by 44.3% in the first quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 8,642 shares of the biopharmaceutical company’s stock valued at $514,000 after acquiring an additional 2,654 shares in the last quarter. Donaldson Capital Management LLC lifted its position in shares of Gilead Sciences by 12.5% in the first quarter. Donaldson Capital Management LLC now owns 5,763 shares of the biopharmaceutical company’s stock valued at $343,000 after acquiring an additional 641 shares in the last quarter. Finally, Ergoteles LLC acquired a new position in Gilead Sciences in the first quarter valued at $2,304,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Company Profile

(Get Free Report)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Further Reading

Insider Buying and Selling by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.